Comparative Pharmacology
Head-to-head clinical analysis: HALFAN versus PLAQUENIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HALFAN versus PLAQUENIL.
HALFAN vs PLAQUENIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.
Antimalarial and immunosuppressant; inhibits heme polymerase in Plasmodium, preventing conversion of toxic heme to hemozoin; also inhibits lysosomal function, antigen presentation, and cytokine production (e.g., IL-1, TNF-alpha) in autoimmune diseases.
Adults: 500 mg orally once daily.
400 mg (310 mg base) orally daily, or 400 mg/day in divided doses; maintenance: 200-400 mg/day
None Documented
None Documented
Terminal elimination half-life is 10-18 hours (mean 14 hours) in healthy adults, allowing twice-daily dosing.
Terminal elimination half-life: 32-50 days (range 22-124 days) due to extensive tissue distribution and slow release from melanin-rich tissues; requires long-term dosing to achieve steady state (3-6 months).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug; biliary/fecal elimination of metabolites approximately 20-30%.
Renal (50-70% unchanged), fecal (20-30% as metabolites), minor biliary.
Category C
Category C
Antimalarial
Antimalarial